Biodistribution and Radiation Dosimetry of the A1 Adenosine Receptor Ligand 18F-CPFPX Determined from Human Whole-body PET

Overview

Journal Eur J Nucl Med Mol Imaging

Specialties Biophysics
Nuclear Medicine
Radiology

Date 2008 Apr 1

PMID 18373090

Citations 7

Authors

Hans Herzog

David Elmenhorst

Oliver Winz

Andreas Bauer

Affiliations

Soon will be listed here.

Abstract

Purpose: (18)F-8-cyclopentyl-3-(3-fluoropropyl)-1-propylxanthine ((18)F-CPFPX) is a potent radioligand to study human cerebral A(1) adenosine receptors and their neuromodulatory and neuroprotective functions with positron emission tomography (PET). The purpose of this study was to determine the biodistribution and the radiation dose of (18)F-CPFPX by whole-body scans in humans.

Methods: Six normal volunteers were examined with 12 whole-body PET scans from 1.5 min to 4.5 h after injection. Volumes of interest were defined over all visually identifiable organs, i.e. liver, gallbladder, kidneys, small intestines, heart, and brain to obtain the organs' volumes and time-activity curves (TACs). TACs were fitted with exponential functions, extrapolated, multiplied with the physical decay and normalized to injected activities so that the residence times could be computed as area under the curve. Radiation doses were calculated using the OLINDA/EXM software for internal dose assessment in nuclear medicine.

Results: The liver uptake shows peak values (decay-corrected) of up to 35% of the injected radioactivity. About 30% is eliminated by bladder voiding. The highest radiation dose is received by the gallbladder (136.2 +/- 66.1 muSv/MBq), followed by the liver (84.4 +/- 10.6 muSv/MBq) and the urinary bladder (78.3 +/- 7.1 muSv/MBq). The effective dose was 17.6 +/- 0.5 muSv/MBq.

Conclusions: With 300 MBq of injected (18)F-CPFPX a subject receives an effective dose (ICRP 60) of 5.3 mSv. Thus the effective dose of an (18)F-CPFPX study is comparable to that of other (18)F-labelled neuroreceptor ligands.

Citing Articles

Purinergic Receptors of the Central Nervous System: Biology, PET Ligands, and Their Applications.

Zarrinmayeh H, Territo P Mol Imaging. 2020; 19:1536012120927609.

PMID: 32539522 PMC: 7297484. DOI: 10.1177/1536012120927609.

An one-pot two-step automated synthesis of [18F]T807 injection, its biodistribution in mice and monkeys, and a preliminary study in humans.

Huang Y, Chiu M, Yen R, Tsai C, Hsieh H, Chiu C PLoS One. 2019; 14(7):e0217384.

PMID: 31260447 PMC: 6602418. DOI: 10.1371/journal.pone.0217384.

An Optimized MicroPET Imaging Method for the Distribution and Synergies of Natural Products.

Cui Q, Liu Y, Zhou M, Han Y, Yin C, Bai G Front Pharmacol. 2018; 9:948.

PMID: 30186178 PMC: 6110851. DOI: 10.3389/fphar.2018.00948.

Considerations in the Development of Reversibly Binding PET Radioligands for Brain Imaging.

Pike V Curr Med Chem. 2016; 23(18):1818-69.

PMID: 27087244 PMC: 5579844. DOI: 10.2174/0929867323666160418114826.

Biodistribution and radiation dosimetry of the integrin marker 18F-RGD-K5 determined from whole-body PET/CT in monkeys and humans.

Doss M, Kolb H, Zhang J, Belanger M, Stubbs J, Stabin M J Nucl Med. 2012; 53(5):787-95.

PMID: 22499613 PMC: 7607669. DOI: 10.2967/jnumed.111.088955.

References

Svenningsson P, Hall H, Sedvall G, Fredholm B . Distribution of adenosine receptors in the postmortem human brain: an extended autoradiographic study. Synapse. 1998; 27(4):322-35. DOI: 10.1002/(SICI)1098-2396(199712)27:4<322::AID-SYN6>3.0.CO;2-E. View

Meyer P, Elmenhorst D, Bier D, Holschbach M, Matusch A, Coenen H . Quantification of cerebral A1 adenosine receptors in humans using [18F]CPFPX and PET: an equilibrium approach. Neuroimage. 2005; 24(4):1192-204. DOI: 10.1016/j.neuroimage.2004.10.029. View

Meyer P, Elmenhorst D, Zilles K, Bauer A . Simplified quantification of cerebral A1 adenosine receptors using [18F]CPFPX and PET: analyses based on venous blood sampling. Synapse. 2005; 55(4):212-23. DOI: 10.1002/syn.20113. View

Herzog H, Zilken H, Niederbremer A, Friedrich W . Calculation of residence times and radiation doses using the standard PC software Excel. Eur J Nucl Med. 1998; 24(12):1514-21. DOI: 10.1007/s002590050182. View

Holschbach M, Olsson R, Bier D, Wutz W, Sihver W, Schuller M . Synthesis and evaluation of no-carrier-added 8-cyclopentyl-3-(3-[(18)F]fluoropropyl)-1-propylxanthine ([(18)F]CPFPX): a potent and selective A(1)-adenosine receptor antagonist for in vivo imaging. J Med Chem. 2002; 45(23):5150-6. DOI: 10.1021/jm020905i. View

CLOUTIER R, Smith S, Watson E, SNYDER W, Warner G . Dose to the fetus from radionuclides in the bladder. Health Phys. 1973; 25(2):147-61. DOI: 10.1097/00004032-197308000-00009. View

Slifstein M, Hwang D, Martinez D, Ekelund J, Huang Y, Hackett E . Biodistribution and radiation dosimetry of the dopamine D2 ligand 11C-raclopride determined from human whole-body PET. J Nucl Med. 2006; 47(2):313-9. View

Brix G, Zaers J, Adam L, Bellemann M, Ostertag H, Trojan H . Performance evaluation of a whole-body PET scanner using the NEMA protocol. National Electrical Manufacturers Association. J Nucl Med. 1997; 38(10):1614-23. View

Holschbach M, Fein T, Krummeich C, Lewis R, Wutz W, Schwabe U . A1 adenosine receptor antagonists as ligands for positron emission tomography (PET) and single-photon emission tomography (SPET). J Med Chem. 1998; 41(4):555-63. DOI: 10.1021/jm9705465. View

10.

Siegel J, Thomas S, STUBBS J, Stabin M, Hays M, Koral K . MIRD pamphlet no. 16: Techniques for quantitative radiopharmaceutical biodistribution data acquisition and analysis for use in human radiation dose estimates. J Nucl Med. 1999; 40(2):37S-61S. View

11.

Fredholm B, IJzerman A, Jacobson K, Klotz K, Linden J . International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors. Pharmacol Rev. 2001; 53(4):527-52. PMC: 9389454. View

12.

Hoffman E, Huang S, Phelps M, Kuhl D . Quantitation in positron emission computed tomography: 4. Effect of accidental coincidences. J Comput Assist Tomogr. 1981; 5(3):391-400. DOI: 10.1097/00004728-198106000-00015. View

13.

Bauer A, Langen K, Bidmon H, Holschbach M, Weber S, Olsson R . 18F-CPFPX PET identifies changes in cerebral A1 adenosine receptor density caused by glioma invasion. J Nucl Med. 2005; 46(3):450-4. View

14.

Ulas J, Brunner L, Nguyen L, Cotman C . Reduced density of adenosine A1 receptors and preserved coupling of adenosine A1 receptors to G proteins in Alzheimer hippocampus: a quantitative autoradiographic study. Neuroscience. 1993; 52(4):843-54. DOI: 10.1016/0306-4522(93)90533-l. View

15.

Herzog H, Coenen H, Kuwert T, Langen K, Feinendegen L . Quantification of the whole-body distribution of PET radiopharmaceuticals, applied to 3-N-([18F]fluoroethyl)spiperone. Eur J Nucl Med. 1990; 16(2):77-83. DOI: 10.1007/BF01465913. View

16.

Fastbom J, Pazos A, Probst A, Palacios J . Adenosine A1 receptors in the human brain: a quantitative autoradiographic study. Neuroscience. 1987; 22(3):827-39. DOI: 10.1016/0306-4522(87)92962-9. View

17.

Meyer P, Bier D, Holschbach M, Boy C, Olsson R, Coenen H . Quantification of cerebral A1 adenosine receptors in humans using [18F]CPFPX and PET. J Cereb Blood Flow Metab. 2004; 24(3):323-33. DOI: 10.1097/01.WCB.0000110531.48786.9D. View

18.

Stabin M, Sparks R, Crowe E . OLINDA/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine. J Nucl Med. 2005; 46(6):1023-7. View

19.

Boy C, Meyer P, Kircheis G, Holschbach M, Herzog H, Elmenhorst D . Cerebral A1 adenosine receptors (A1AR) in liver cirrhosis. Eur J Nucl Med Mol Imaging. 2007; 35(3):589-97. DOI: 10.1007/s00259-007-0586-z. View

20.

Lu J, Ichise M, Liow J, Ghose S, Vines D, Innis R . Biodistribution and radiation dosimetry of the serotonin transporter ligand 11C-DASB determined from human whole-body PET. J Nucl Med. 2004; 45(9):1555-9. View